产品中心
当前位置：首页>产品中心Anti-OLFM4/PE-Cy3
货号： bs-6558R-PE-Cy3 基本售价： 2980.0 元 规格： 100ul
产品信息
- 产品编号
- bs-6558R-PE-Cy3
- 英文名称
- Anti-OLFM4/PE-Cy3
- 中文名称
- PE-Cy3标记的抗细胞凋亡蛋白OLFM44抗体
- 别 名
- Antiapoptotic protein GW112; G-CSF-stimulated clone 1 protein; GC1; GW112; hGC 1; hGC-1; hOLfD; olfactomedin 4; Olfactomedin-4; OlfD; OLFM4; OLFM4_HUMAN; OLM4.
- 规格价格
- 100ul/2980元购买 大包装/询价
- 说 明 书
- 100ul
- 研究领域
- 肿瘤 肿瘤细胞生物标志物
- 抗体来源
- Rabbit
- 克隆类型
- Polyclonal
- 交叉反应
- Human, Mouse, Rat, Dog, Pig, Cow, Rabbit,
- 产品应用
- IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
- 分 子 量
- 55kDa
- 性 状
- Lyophilized or Liquid
- 浓 度
- 1mg/ml
- 免 疫 原
- KLH conjugated synthetic peptide derived from human OLFM4
- 亚 型
- IgG
- 纯化方法
- affinity purified by Protein A
- 储 存 液
- 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
- 保存条件
- Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
- 产品介绍
- background:
Olfactomedin-4, also known as G-CSF-stimulated clone 1 protein, Antiapoptotic protein GW112, and OLFM4, is a secreted protein which contains one olfactomedin-like domain. OLFM4 is expressed during myeloid lineage development. It is strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. OLFM4 is highly expressed in pancreatic cancer tissues and shows an elevated expression level during the early S phase of the cell cycle. It is also expressed at high levels in stomach cancer and colon cancer tissues. Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression. OLFM4 is an antiapoptotic factor that promotes tumor growth. OLFM4 promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. OLFM4 also facilitates cell adhesion. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19. The human OLFM4 is also thought to be a useful marker for early myeloid development.
Function:
May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin.
Subunit:
Homomultimer; disulfide-linked. Interacts with NDUFA13. Interacts with cell surface lectins (locutions ricinus communis agglutinin I, concanavalin-A and wheat germ agglutinin) and cadherin.
Subcellular Location:
Secreted, extracellular space. Mitochondrion. Note=Subcellular location is not clearly defined: has been shown to be secreted (PubMed:16566923), but also in the mitochondrion (PubMed:15059901 and PubMed:20724538), cytoplasm and plasma membrane (PubMed:20724538) and in the nucleus (PubMed:15059901).
Tissue Specificity:
Expressed during myeloid lineage development. Much higher expression in bone marrow neutrophils than in peripheral blood neutrophils (at protein level). Strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. Overexpressed in some pancreatic cancer tissues.
Post-translational modifications:
N-glycosylated.
Similarity:
Contains 1 olfactomedin-like domain.
Database links:Entrez Gene: 467367 Chimpanzee
Entrez Gene: 515082 Cow
Entrez Gene: 485470 Dog
Entrez Gene: 10562 Human
Entrez Gene: 380924 Mouse
Entrez Gene: 290409 Rat
Omim: 614061 Human
SwissProt: Q6UX06 Human
SwissProt: Q3UZZ4 Mouse
Unigene: 508113 Human
Unigene: 26456 Mouse
Unigene: 156265 Rat
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.